Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat for pulmonary vascular resistance reduction in heart failure with combined postcapillary pulmonary hypertension
ChiCTR2300072617Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of vericiguat in heart failure (HF) and pulmonary hypertension (PH) (2 arms), sponsored by The Affiliated Hospital of Guangdong Medical University. Primary endpoint: Change in pulmonary vascular resistance. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
vericiguat
03
Conditions
heart failure (HF)pulmonary hypertension (PH)
Beyond the preview
Go deeper on ChiCTR2300072617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072617.